These results strongly support further development acceleration.
VLA1553 was generally safe in all dose groups.
- Well-tolerated in the low and medium dose (Superior safety profile, including viremia, compared to the high dose group)
- Excellent local tolerability
Excellent immunogenicity profile in all dose groups after a single vaccination
- 100% Seroconversion1 achieved at Day 14 after a single vaccination in all dose groups
- Sustained at 100% after six months